Teprotumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Teprotumumab
Accession Number
DB06343
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

A fully human IgG1 type monoclonal antibody directed against the human insulin-like growth factor-I receptor.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer
External IDs
R-1507 / R1507 / RG-1507 / RG1507 / RO-4858696 / RO-4858696-000 / RO-4858696000 / RO4858696 / RO4858696-000 / RV-001 / RV001
Categories
UNII
Y64GQ0KC0A
CAS number
1036734-93-6

Pharmacology

Indication

Investigated for use/treatment in solid tumors.

Pharmacodynamics
Not Available
Mechanism of action

R1507 (formerly called Roche 1) is a fully human antibody which targets the Insulin-like Growth factor-1 Receptor (IGF-1R). The IGF-1R molecule has been shown to be important in tumor growth and protecting tumor cells from being killed. IGF-1R is over-expressed on a variety of tumors including breast, colon, prostate, lung, skin and pancreatic cancers and is a well validated target for an antibody therapeutic approach. [Genmab Website]

TargetActionsOrganism
UInsulin-like growth factor 1 receptorNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Teprotumumab.
AbituzumabThe risk or severity of adverse effects can be increased when Teprotumumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Teprotumumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Teprotumumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Teprotumumab.
AducanumabThe risk or severity of adverse effects can be increased when Teprotumumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Teprotumumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teprotumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Teprotumumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Teprotumumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Teprotumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceCancer, Breast1
1CompletedTreatmentDiabetic Macular Edema (DME)1
1CompletedTreatmentNeoplasms2
1TerminatedTreatmentNeoplasms2
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentOphthalmopathy, Thyroid-Associated / Thyroid Associated Ophthalmopathy1
2CompletedTreatmentSarcomas1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentGraves' Orbitopathy / Thyroid Eye Disease1
3Enrolling by InvitationTreatmentThyroid Eye Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein tyrosine kinase activity
Specific Function
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involv...
Gene Name
IGF1R
Uniprot ID
P08069
Uniprot Name
Insulin-like growth factor 1 receptor
Molecular Weight
154791.73 Da

Drug created on March 19, 2008 10:25 / Updated on June 04, 2019 06:23